Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 5/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10067342 | 0.87 | LMNA (0.72) | NPSR1MAPTCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL10067355 | 0.85 | LMNA (0.70) | NPSR1MAPTTSHRSMN1; SMN2LMNA | |
| SCHEMBL10067354 | 0.85 | LMNA (0.70) | NPSR1MAPTTSHRSMN1; SMN2LMNA | |
| SCHEMBL10067347 | 0.79 | TSHR (0.64) | NPSR1MAPTCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL10067350 | 0.77 | ALDH1A1 (0.71) | MAPTTSHRSMN1; SMN2MEN1KMT2A | |
| SCHEMBL10067306 | 0.76 | TSHR (0.44) | NPSR1MAPTCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL14448728 | 0.74 | ALDH1A1 (0.62) | MAPTSMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL11601199 | 0.74 | ALDH1A1 (0.71) | MAPTSMN1; SMN2MEN1KMT2AL3MBTL1 | |
| SCHEMBL11605552 | 0.73 | ALDH1A1 (0.60) | MAPTSMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL9776542 | 0.71 | MAPT (0.71) | NPSR1MAPTCYP2C19TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148392-B2 | 2-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatment of cancer | LORUS THERAPEUTICS INC. (CA) | 2012-04-03 | — | — | US | disclosed |
| US-8148392-B2 | 2-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatment of cancer | LORUS THERAPEUTICS INC. (CA) | 2012-04-03 | — | — | US | disclosed |
| US-20100168417-A1 | 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer | APTOSE BIOSCIENCES INC. (CA) | 2010-07-01 | — | — | US | disclosed |
| US-20100168417-A1 | 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer | APTOSE BIOSCIENCES INC. (CA) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168417-A1 | 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer | FLI1, IKZF3, IKZF2 | NPSR1 4684/4885MAPT 4513/4885CYP1A2 1955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.